Postpartum Dysgalactia Syndrome (PDS) in Sauen (2023–2025) | USA vs. EUR:

1) What is PDS Today? A Syndrome, Not a Single Disease

PDS is defined clinically by impaired colostrum/milk production and/or inflammation of the mammary gland(s), often within the first 12–72 hours postpartum. The practical hallmark is not always the sow's appearance, but the behavior and condition of piglets—restlessness, frequent nursing attempts, fighting, hollow flanks, dehydration, and heterogeneous growth. Recent reviews emphasize that piglet observation is often more sensitive than sow behavior alone, because many healthy sows are naturally sedentary immediately after farrowing.

The term "MMA" is increasingly recognized as too narrow: not all cases include uterine infection, overt mastitis, or complete agalactia. The contemporary framing is a postpartum syndrome that may include mastitis and metritis as components, but is strongly influenced by sow physiology and management during the periparturient transition.

2) The Most Important 2023–2025 Clinical Insight: Immune Activation and Metabolic Strain

A major shift in the recent literature is the growing evidence that PDS is associated with systemic metabolic and inflammatory alterations, not only local mammary infection.

2.1 Biomarkers: PDS Sows Look "Immune-Activated"

A 2024 Journal of Animal Science study evaluating circulating immune cells and inflammatory analytes found that sows with PDS showed signs of altered metabolism and immune activation relative to controls. Inflammatory biomarkers such as lipopolysaccharide-binding protein (LBP) increased in PDS animals, consistent with endotoxin exposure and systemic inflammatory response processes. The authors conclude that PDS sows appear immune-activated and that further work is needed to determine whether PDS can be predicted at farrowing.

This is consequential for herd management: it suggests PDS may have a detectable physiological trajectory—potentially enabling earlier identification and intervention before major piglet impacts occur.

2.2 "Infection-Only" Models Are Increasingly Insufficient

PDS has historically been treated as primarily coliform mastitis. Contemporary reviews highlight that bacteria may be present in milk of both healthy and affected sows, and that PDS cannot be explained solely by bacterial exposure. Instead, sow susceptibility (immune competence, metabolic status, stressors, farrowing difficulty) likely shapes whether postpartum bacterial challenge translates into clinically significant dysgalactia. This aligns with the immune-activation findings above and supports a shift toward prevention through transition management rather than reactive medication alone.

3) Diagnosis (2023–2025): The Movement Toward Structured Assessment and Early Detection Tools

3.1 Why Clinical Diagnosis is Still Hard

PDS remains predominantly a clinical diagnosis, but several developments are relevant:

• Clinical signs can be subtle; sow lethargy is not reliable because most sows rest post-farrowing.
• Udder palpation and milk stripping remain important, but time-intensive.
• Piglet indicators (restlessness, poor satiation, vocalization patterns, diarrheal risk) are often earlier and more consistent.

Recent reviews reinforce that structured clinical criteria plus piglet-based observation are more effective than relying on fever alone.

3.2 Thermography and Udder Imaging: Practical, Non-Invasive Additions

Thermal imaging has gained attention as a tool to detect mammary inflammation and potentially support early diagnosis. Controlled evaluations of infrared thermography and ultrasonography show that these approaches can complement clinical udder exams in sows, supporting earlier and more objective detection of mammary pathology.

While this is not yet a universal farm technology, it is a meaningful signal: PDS detection is moving toward objective measurement, which could improve consistency in large units and enable targeted therapy rather than blanket treatment.

4) Management and Prevention: Evidence-Based Priorities for Modern Sow Systems

Because PDS is multifactorial, the strongest interventions tend to be systems-based rather than single-drug solutions.

4.1 Transition Feeding and Constipation Prevention Remain Core

Recent synthesis work again emphasizes the role of:

• Avoiding constipation and improving gut motility via fiber strategies in late gestation
• Ensuring abundant water intake
• Avoiding abrupt overfeeding immediately postpartum
• Maintaining thermal comfort (cooling the sow while providing piglet microclimate heat)

These factors reduce physiologic stress and may reduce inflammatory triggers.

4.2 Postpartum NSAID Administration: Strong Evidence for Improving Piglet Outcomes

A widely cited 2023 Journal of Animal Science study evaluated postpartum meloxicam administration and found improved piglet outcomes, including growth and reduced health/medical usage effects, compared with split-suckling alone. This reinforces the current view that early postpartum pain and inflammation control can improve nursing performance and piglet viability.

Even though PDS is not purely pain-driven, NSAIDs appear to:

• reduce systemic inflammation
• improve sow comfort and feed intake
• support better milk production or letdown patterns
• reduce downstream piglet disease pressure

4.3 Targeted Antibiotic Therapy, Not Default Prophylaxis

The clinical literature increasingly discourages routine prophylactic antimicrobial use for PDS prevention. Instead:

• treat only when mastitis/systemic illness is likely
• pair antibiotic therapy with NSAID and supportive measures
• consider sampling where feasible

This is especially prominent in Europe due to regulation (next section), but the trend exists globally.

5) The US vs Europe Comparison: Same Biology, Different System Incentives

Across both regions, the biology of PDS is similar. The differences are primarily structural: regulation, antimicrobial norms, and adoption of preventive protocols.

5.1 Antibiotic Regulation is the Largest Policy Difference

Europe: Regulation (EU) 2019/6, effective in consolidated form from 2022, is a central reference point for tightening veterinary medicinal product use. It is widely cited as a driver of restricting routine prophylaxis and encouraging husbandry-based disease prevention.

Advocacy and policy analyses discussing implementation emphasize that these rules aim to end routine farm antibiotic use and prevent antibiotics from compensating for poor management.

United States: The US has moved toward stricter veterinary oversight and reduced medically important antibiotic use, but it generally does not mirror the EU's explicit prohibition style. As a result, the US tends to retain more flexibility for metaphylaxis and broader antimicrobial intervention where veterinarians deem risk high—though stewardship pressure is increasing.

Implication for PDS:

• Europe is structurally incentivized to rely on prevention, NSAIDs, hygiene, and monitoring, and to treat with antibiotics selectively.
• The US can more readily use antibiotic interventions, but is also trending toward prevention-first strategies.

5.2 Practical Herd-Level Differences

Europe

Higher pressure to reduce antibiotics drives adoption of:

• routine or semi-routine postpartum NSAID use where justified
• stronger emphasis on hygiene protocols
• increasing interest in precision monitoring technologies (e.g., thermal imaging)

US

• Many large systems deploy strong standard operating procedures and staff-based monitoring.
• NSAID use occurs but may be more variable due to product approvals, residue concerns, and system preferences.
• PDS management often remains treatment-forward, though transition management is increasingly emphasized.

6) What is "New" in 2023–2025, and What It Means for Herd Strategy

6.1 Key Scientific Advances

• Biomarker evidence of immune activation and metabolic disruption is becoming clearer, suggesting PDS can be approached as a systemic postpartum inflammatory syndrome rather than solely mastitis.
• NSAID postpartum interventions have robust controlled evidence showing improved piglet outcomes, supporting integration into herd protocols under veterinary guidance.
• Thermography and imaging show practical promise for objective udder-health assessment.
• Comprehensive review work continues to refine best practice in detection (piglet-focused) and prevention (transition management and environmental comfort).

6.2 Implications for Modern Farms

A high-functioning PDS program in 2025 looks like:

Prevention-first transition program

• fiber + constipation control
• careful postpartum feed escalation
• high water availability
• thermal comfort and hygiene

Structured postpartum monitoring

• check udder and milk availability
• piglet-based early warning
• consider objective tools (thermography) where scale warrants it

Standardized early response protocol

• NSAID administration under veterinary protocol
• oxytocin only when milk letdown is impaired and with cautious dosing
• antibiotics only when clinical picture supports infection/systemic illness

This approach is compatible with both US and European systems, but Europe is structurally pushed further in this direction by antimicrobial policy and monitoring expectations.

7) Research Gaps and Where 2025 Research is Heading

Despite progress, several gaps remain:

• Predictive diagnostics: biomarkers like LBP and metabolomic signatures suggest possibility of prediction, but practical predictive tools are still under development.
• Causality resolution: disentangling whether inflammation causes dysgalactia, or dysgalactia leads to inflammation, remains complex.
• Precision interventions: identifying which sows benefit most from NSAIDs, nutritional interventions, or monitoring technology would improve cost-effectiveness.
• Standardized case definitions: cross-study comparisons remain difficult without consistent diagnostic criteria, which affects incidence estimates and benchmarking.

Conclusion

Between 2023 and 2025, PDS research has moved away from purely infection-centered explanations toward a model emphasizing systemic inflammation, immune activation, and metabolic strain during the postpartum transition. Evidence increasingly supports that improving sow comfort and controlling inflammation—particularly via postpartum NSAIDs—can yield measurable piglet health and productivity benefits. Technologies such as infrared thermography and ultrasonography show potential to improve early detection and standardize udder assessment.

The core difference between the US and Europe lies less in biology and more in system design and policy incentives, especially antimicrobial regulation. Europe's constraints on prophylactic use accelerate adoption of prevention-first programs and encourage objective monitoring and non-antibiotic interventions. The US is trending in the same direction through stewardship initiatives and evidence-based protocols, but retains comparatively more flexibility in antimicrobial approaches.

For producers and veterinarians, the best-supported strategy in 2025 is a structured periparturient management program that reduces known risk factors, standardizes early detection, and uses therapeutics (NSAIDs and antibiotics) in a targeted, protocol-driven manner backed by clinical assessment and—where feasible—objective diagnostic tools.

---

Weiterführende Artikel: Erfahren Sie, wie Nestbauverhalten PDS 24 Stunden vor klinischen Symptomen vorhersagen kann, oder entdecken Sie, wie smarte Ohrmarken Beschleunigungs- und Temperaturdaten nutzen für Precision Livestock Monitoring. Mehr über BioCV's Ansatz zum Sauenmanagement.